Involvement of 27-Hydroxycholesterol in Mitotane Action on Adrenocortical Carcinoma
Adrenocortical carcinoma (ACC) is a rare cancer with poor prognosis. Mitotane, the standard treatment for ACC, impairs adrenocortical steroid biosynthesis and cholesterol metabolism. In the H295R cell line, a standard ACC in vitro model, mitotane was previously reported to enhance the production of...
Main Authors: | Antonina Germano, Daniela Rossin, Valerio Leoni, Noemi Iaia, Laura Saba, Vittoria Basile, Soraya Puglisi, Claudio Caccia, Giuseppe Poli, Fiorella Biasi, Massimo Terzolo |
---|---|
Format: | Article |
Language: | English |
Published: |
MDPI AG
2020-04-01
|
Series: | Cells |
Subjects: | |
Online Access: | https://www.mdpi.com/2073-4409/9/4/885 |
Similar Items
-
Recovery of Adrenal Insufficiency Is Frequent After Adjuvant Mitotane Therapy in Patients with Adrenocortical Carcinoma
by: Jonathan Poirier, et al.
Published: (2020-03-01) -
Mitotane Concentrations Influence the Risk of Recurrence in Adrenocortical Carcinoma Patients on Adjuvant Treatment
by: Soraya Puglisi, et al.
Published: (2019-11-01) -
Clinical results of the use of mitotane for adrenocortical carcinoma
by: A.A. Kasperlik-Zaluska
Published: (2000-10-01) -
What Is the Optimal Duration of Adjuvant Mitotane Therapy in Adrenocortical Carcinoma? An Unanswered Question
by: Vittoria Basile, et al.
Published: (2021-04-01) -
Population Pharmacokinetics Modelling and Simulation of Mitotane in Patients with Adrenocortical Carcinoma: An Individualized Dose Regimen to Target All Patients at Three Months?
by: Yoann Cazaubon, et al.
Published: (2019-10-01)